Clinical Characteristics and Concordance of Anti‐ MDA5 Antibodies: A Multicenter Australian Study
Arthritis Care & Research · 04.09.2026
DOI: 10.1002/acr.80144 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 04.09.2026. Verfasst von Syed B Ali und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Allergy, Flinders Medical Centre, Bedford Park, South Australia, Australia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
In Australia, anti‐MDA5 antibodies are exclusively tested by a line immunoblot assay (LIA). The clinical concordance of an LIA‐positive anti‐MDA5 result is unclear. We aimed to describe the clinical features and determine the clinical concordance of patients with anti‐MDA5 antibodies.
Methods
Electronic records of a multisite cohort (patients with positive anti‐MDA5 on LIA from three states in Australia from January 2017 to September 2024) were reviewed for clinical features of dermatomyositis (cutaneous manifestations, proximal weakness, interstitial lung disease [ILD]), laboratory investigations and other myositis autoantibodies, and imaging pertaining to the muscles and lungs.
Results
Complete clinical data were available for 108 of 118 patients with anti‐MDA5 antibodies. A positive test was determined to be clinically concordant in 21 of 108 (19.4%) patients; these patients had higher signal intensity than those with clinical discordance (52 vs 19.5; P < 0.0001). The median age was 65 years (interquartile range 48–74), and 67% were female. The cohort was predominantly White (n = 14), followed by Southeast Asian (n = 3), African (n = 3), and Middle Eastern (n = 1). All 21 patients with anti‐MDA5 dermatomyositis had ILD; 7 of 9 with rapidly progressive ILD (RP‐ILD) were deceased at time of review. Patients with RP‐ILD had higher ferritin levels (1,226 vs 262 μg/L; P < 0.05) and a higher neutrophil to lymphocyte ratio (4.1 vs 2.6; P < 0.05) than patients without RP‐ILD. Pneumomediastinum developed in 7 of 21 (33%); of these, 6 had RP‐ILD, and 4 subsequently died. Other manifestations included myositis (n = 8), cutaneous features (n = 14), polyarthritis (n = 6), and myocarditis (n = 1).
Conclusion
Higher anti‐MDA5 signal intensity on LIA was associated with greater clinical concordance. Pneumomediastinum is common and associated with high mortality.
Autor:innen und Institutionen
- Department of Clinical Immunology and Allergy, Flinders Medical Centre, Bedford Park, South Australia, Australia.
- School of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.
- School of Medicine, Adelaide University, Adelaide, South Australia, Australia.
- Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Rheumatology Unit, Southern Adelaide Local Health Network, Bedford Park, South Australia, Australia.
- Department of Rheumatology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
ORCID-Profile: Syed B Ali, Jessica Day
Zitieren
APA
Ali, S. B., Khoo, T., Shivakumar, K., Caroll, A., Hender, L., Beroukas, D., Griggs, K., Jin, C., De Malmanche, T., Day, J., Major, G., & Limaye, V. (2026). Clinical Characteristics and Concordance of Anti‐ MDA5 Antibodies: A Multicenter Australian Study. Arthritis Care & Research. https://doi.org/10.1002/acr.80144
Vancouver
Ali SB, Khoo T, Shivakumar K, Caroll A, Hender L, Beroukas D, et al. Clinical Characteristics and Concordance of Anti‐ MDA5 Antibodies: A Multicenter Australian Study. Arthritis Care & Research. 2026. doi:10.1002/acr.80144
BibTeX
@article{Ali2026,
author = {Ali, Syed B and Khoo, Thomas and Shivakumar, Keeran and Caroll, Adam and Hender, Lauren and Beroukas, Dimitra and Griggs, Kim and Jin, Celina and De Malmanche, Theo and Day, Jessica and Major, Gabor and Limaye, Vidya},
title = {Clinical Characteristics and Concordance of Anti‐ MDA5 Antibodies: A Multicenter Australian Study},
journal = {Arthritis Care & Research},
year = {2026},
doi = {10.1002/acr.80144}
}
EUVIMED